Chemomab Therapeutics Ltd - ADR

NASDAQ:CMMB   3:08:07 PM EDT
5.32
+0.19 (+3.70%)
Products

Chemomab Announces FDA Clearance Of IND Application For CM-101

Published: 12/02/2021 13:09 GMT
Chemomab Therapeutics Ltd - ADR (CMMB) - Chemomab Announces FDA Clearance of Its Ind Application for Cm-101, a First-in-class Ccl24 Neutralizing Antibody for the Treatment of Primary Sclerosing Cholangitis.
Chemomab - Phase 2 Spring Trial Assessing Cm-101 As Potential Treatment for Psc is Underway in Europe, Israel.
Chemomab Therapeutics - Phase 2 Spring Trial Assessing Cm-101 As a Potential Treatment for Psc is Now Being Expanded to Include U.S. Sites.
Chemomab Therapeutics - Initial Clinical Readout From Spring Trial is Expected in 2022.